A Randomized, Open Labeled, Multicenter Clinical Trial on the Effectiveness and Safety of the 5-HT3-Receptor Antagonist Ramosetron in Male Patients With Irritable Bowel Syndrome With Diarrhea: Comparison With Mebeverine

被引：0
|
作者：
Lee, Kwang Jae
Rhee, Poong-Lyul
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S606 / S606
页数：1
相关论文
共 29 条
  • [1] Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine
    Lee, K. J.
    Kim, N. Y.
    Kwon, J. K.
    Huh, K. C.
    Lee, O. Y.
    Lee, J. S.
    Choi, S. C.
    Sohn, C. I.
    Myung, S. J.
    Park, H. J.
    Choi, M. K.
    Bak, Y. T.
    Rhee, P. L.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 23 (12): : 1098 - E540
  • [2] Anterior resection syndrome: a randomized clinical trial of a 5-HT3 receptor antagonist (ramosetron) in male patients with rectal cancer
    Ryoo, S-B
    Park, J. W.
    Lee, D. W.
    Lee, M. A.
    Kwon, Y-H
    Kim, M. J.
    Moon, S. H.
    Jeong, S-Y
    Park, K. J.
    BRITISH JOURNAL OF SURGERY, 2021, 108 (06) : 644 - 651
  • [3] Effects of Ramosetron on Male Patients With Irritable Bowel Syndrome With Diarrhea: Randomized, Placebo-Controlled Trial
    Fukudo, Shin
    Ida, Motoko
    Akiho, Hikaru
    Nakashima, Yoshihiro
    Matsueda, Kei
    GASTROENTEROLOGY, 2013, 144 (05) : S545 - S545
  • [4] A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome
    Matsueda, K.
    Harasawa, S.
    Hongo, M.
    Hiwatashi, N.
    Sasaki, D.
    DIGESTION, 2008, 77 (3-4) : 225 - 235
  • [5] A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome
    Matsueda, Kei
    Harasawa, Shigeru
    Hongo, Michio
    Hiwatashi, Nobuo
    Sasaki, Daisuke
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2008, 43 (10) : 1202 - 1211
  • [6] Experimental model of irritable bowel syndrome using conditioned fear response and the effectiveness of 5-HT3 receptor antagonist ramosetron in the model
    Funatsu, T
    Hirata, T
    Keto, Y
    Sasamata, M
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 107P - 107P
  • [7] A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
    Camilleri, M
    Chey, WY
    Mayer, EA
    Northcutt, AR
    Heath, A
    Dukes, GE
    McSorley, D
    Mangel, AM
    ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (14) : 1733 - 1740
  • [8] Review article:: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients
    Mangel, AW
    Northcutt, AR
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 : 77 - 82
  • [9] A randomized clinical trial comparing the efficacy of ramosetron-trimebutine dual therapy vs trimebutine monotherapy in male patients with irritable bowel syndrome with diarrhea (IBS-D)
    Rim, D. H.
    Lee, O. Y.
    Lee, K. N.
    Jun, D. W.
    Lee, H. L.
    Yoon, B. C.
    Choi, H. S.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2016, 28 : 100 - 101
  • [10] Efficacy of serotonin type 3 receptor antagonist ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome with inactive Crohn's disease, a pilot trial
    Nakamura, K.
    Tomita, T.
    Oshima, T.
    Fukui, H.
    Watari, J.
    Miwa, H.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 : 55 - 55
123